2024.03.27
Press Release
Submission of Clinical Trial Protocol Notice for Corneal Endothelial Therapy Cell Therapy, “AE101”
ActualEyes Inc. is pleased to announce the submission of the Phase II clinical trial protocol for “AE101,” a cutting-edge therapy for the treatment of bullous keratopathy, to the Pharmaceuticals and Medical Devices Agency (PMDA). After PMDA’s 30-day investigation of the clinical trial protocol, we anticipate commencing the clinical trial.